Orthocell appoints US-based distributors

Fresh from receiving clearance from the Food and Drug Administration to distribute its nerve repair product Remplir in the US earlier this month, Murdoch-based Orthocell has appointed an initial four distributors.

The Paul Anderson-led biotech medical company, which is keen to compete within the $US1.6 billion nerve repair market, said the four distributors held existing key relationships in the states of Colorado, Indiana, Michigan and Virginia.

“The distributor model is an excellent fit for us in the US,” Mr Anderson said.

“It allows us to partner with distributors that have existing strong relationships and established sales channels with both surgeons and hospitals which means we only need a small, but experienced, on-the-ground team of in-house employees. 

“We are expecting to have around ten distributors in place by the end of our financial year, which would account for representation in approximately twenty-five states.”

Orthocell last traded at $1.23, up 5 per cent as of 11.40am AWST.